Healthcare / BiotechnologyNasdaqGS
$0.87
+0.00 (+0.12%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-91.5M · quality 68.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
36/100
D
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$189M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-73.5%
↓Gross Margin
N/A
•Debt/Equity
0.09
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2020–2025 · 5 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
—
FCF / Net income
0.76x
Latest source
Provider fallback
Margin decomposition
Último año: revenue — · net income $-90.6M · FCF $-68.9M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Income Statement | |||||||
| Net Income | $-90.6M | $-90.6M | $-111.1M | $-124.1M | $-123.7M | $-72.7M | $-38.4M |
| EBITDA | $-84.9M | $-84.9M | $-107.5M | $-122.5M | $-119.2M | $-69.8M | $-36.4M |
| EPS | — | — | -1.31 | -1.68 | -2.76 | -4.10 | — |
| Balance Sheet | |||||||
| Debt/Equity | 0.09 | 0.09 | 0.15 | 0.09 | 0.06 | — | — |
| Current Ratio | 5.75 | 5.75 | — | — | — | — | — |
| Cash Flow | |||||||
| Free Cash Flow | $-68.9M | $-68.9M | $-91.5M | $-103.3M | $-125.1M | $-85.9M | $-45.2M |
| Returns | |||||||
| ROE | -73.5% | -73.5% | -119.7% | -89.0% | -50.8% | -26.1% | 47.2% |
| Valuation | |||||||
| P/B | 1.53 | 1.53 | 1.39 | 1.57 | 0.36 | — | — |
| Growth & Yield | |||||||
| EPS Growth | — | — | 22.0% | 39.1% | — | — | — |
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+89.1%
Start / end P/E
n/dx → n/dx
EPS bridge
-1.31 → n/d
Residual
+89.1%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.